Anti-PD-1 approaches—important steps forward in metastatic melanoma

被引：9
|
作者：
Mina Razzak
机构：
来源：
Nature Reviews Clinical Oncology | 2013年 / 10卷 / 7期
关键词：
D O I：
10.1038/nrclinonc.2013.98
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：365 / 365
相关论文
共 50 条
  • [41] A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma
    Weber, Jeffrey S.
    Sznol, Mario
    Sullivan, Ryan J.
    Blackmon, Shauna
    Boland, Genevieve
    Kluger, Harriet M.
    Halaban, Ruth
    Bacchiocchi, Antonietta
    Ascierto, Paolo A.
    Capone, Mariaelena
    Oliveira, Carlos
    Meyer, Krista
    Grigorieva, Julia
    Asmellash, Senait G.
    Roder, Joanna
    Roder, Heinrich
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (01) : 79 - 86
  • [42] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [43] Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma
    Liniker, E.
    Kong, B.
    Menzies, A. M.
    Cooper, A.
    Ramanujam, S.
    Lo, S.
    Kefford, R. F.
    Fogarty, G. B.
    Guminski, A.
    Wang, T. W.
    Carlino, M. S.
    Hong, A.
    Long, G. V.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S664 - S664
  • [44] Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1
    Robert, Caroline
    Lebbe, Celeste
    Lesimple, Thierry
    Lundstrom, Eija
    Nicolas, Valerie
    Gavillet, Bruno
    Crompton, Philippa
    Baroudjian, Barouyr
    Routier, Emilie
    Lejeune, Ferdy J.
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 858 - 865
  • [45] Germline variation in PDCD1 is associated with survival in metastatic melanoma after anti-PD-1 monotherapy
    De With, M.
    Hurkmans, D. P.
    Oomen-de Hoop, E.
    Lalouti, A.
    Bins, S.
    El Bouazzaoui, S.
    Debets, R.
    Aerts, J. G.
    Van Schaik, R. H. N.
    Mathijssen, R. H.
    Van der Veldt, A. A. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S758 - S758
  • [46] PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
    Parakh, Sagun
    Musafer, Ashan
    Paessler, Sabrina
    Witkowski, Tom
    Suen, Connie S. N. Li Wai
    Tutuka, Candani S. A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Scolyer, Richard A.
    Cebon, Jonathan
    Dobrovic, Alexander
    Long, Georgina V.
    Klein, Oliver
    Behren, Andreas
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [47] Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?
    Davies, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1645 - +
  • [48] Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients.
    Brunot, Angelique
    Jeudy, Geraldine
    Tas, Mathieu
    Guillot, Bernard
    Kramkimel, Nora
    Mortier, Laurent
    Mansard, Sandrine
    Lebbe, Celeste
    Blom, Astrid
    Le Corre, Yannick
    Montaudie, Henri
    Prey, Sorilla
    Campillo-Gimenez, Boris
    Lesimple, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma
    Xie, Kuixia
    Peng, Yonglin
    Zhong, Wenying
    Liu, Xinhua
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2022, 27 (03):
  • [50] Impact of Anti-PD-1 Treatment in Patients with Metastatic Melanoma Brain Lesions Treated with Stereotactic Radiosurgery
    Goel, A.
    Kumar, R. J.
    Linam, J. M.
    Huang, A. J.
    Abendroth, R. E.
    Lee, J. W.
    Andrews, B.
    Leong, S.
    Leng, L. Z.
    Minor, D.
    Nosrati, M.
    Vosoughi, E.
    Miller, J.
    Kashani-Sabet, M.
    Kim, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E75 - E75
12345